Skip to main content

Table 3 Adverse events reported in >3 patients overall

From: DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study

Adverse event* Vandetanib 100 mg
(n= 10)
n(%)
Vandetanib 300 mg
(n= 12)
n(%)
Total (n= 22)
n(%)
Fatigue 6 (60) 7 (58) 13 (59)
Rash 2 (20) 10 (83) 11 (50)
Diarrhea 2 (20) 7 (58) 9 (41)
Dry mouth 2 (20) 4 (33) 6 (27)
Nausea 3 (30) 3 (25) 6 (27)
Anorexia 3 (30) 2 (17) 5 (23)
Dysphonia 1 (10) 4 (33) 5 (23)
Abdominal pain 1 (10) 3 (25) 4 (18)
Acne 0 4 (33) 4 (18)
Cough 1 (10) 3 (25) 4 (18)
Dizziness 3 (30) 1 (8) 4 (18)
Dry skin 1 (10) 3 (25) 4 (18)
Flatulence 1 (10) 3 (25) 4 (18)
Hypertension 1 (10) 3 (25) 4 (18)
Insomnia 3 (30) 1 (8) 4 (18)
Nasopharyngitis 2 (20) 2 (17) 4 (18)
Peripheral edema 4 (40) 0 4 (18)
Sinus tachycardia 1 (10) 3 (25) 4 (18)
Weight decreased 1 (10) 3 (25) 4 (18)
  1. *MedDRA-preferred term except for rash
  2. MedDRA grouped term, which includes the following preferred terms: dry skin, erythema, photosensitivity reaction, rash papular, rash pustular, dermatitis allergic, exfoliative rash, and rash erythematous